Cover Image
市場調查報告書

消化性潰瘍:開發中產品分析

Peptic Ulcers - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 213113
出版日期 內容資訊 英文 57 Pages
訂單完成後即時交付
價格
Back to Top
消化性潰瘍:開發中產品分析 Peptic Ulcers - Pipeline Review, H1 2016
出版日期: 2016年06月15日 內容資訊: 英文 57 Pages
簡介

所謂消化性潰瘍是指食道、胃臟內側或小腸上發生的開放性創傷及潰瘍。主要症狀有噁心·嘔吐,及原因不明的體重減輕、食慾變化,腹痛等。主要致病風險要素有吸煙及酒精成癮。主要的治療方法有抗生素和制酸劑,解酸劑,質子幫浦抑制劑等。

本報告提供全球各國治療消化性潰瘍所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

消化性潰瘍概要

治療藥的開發

  • 消化性潰瘍開發中產品:概要
  • 消化性潰瘍開發中產品:比較分析

各企業開發中的消化性潰瘍治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

消化性潰瘍治療藥:開發中的產品一覽(各企業)

消化性潰瘍治療藥的開發企業

  • Ache Laboratorios Farmaceuticos S/A
  • Astellas Pharma Inc.
  • ChoDang Pharm Co., Ltd.
  • Daewoong Pharmaceutical Co., Ltd.
  • Kukje Pharmaceutical Industry Co., Ltd.
  • RaQualia Pharma Inc.
  • Sequella, Inc.
  • Sihuan Pharmaceutical Holdings Group Ltd.
  • Sinil Pharmaceutical Co., Ltd
  • Yooyoung Pharmaceutical Co., Ltd.

消化性潰瘍:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

消化性潰瘍治療藥:開發暫停的產品

消化性潰瘍治療藥:開發中止的產品

消化性潰瘍相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿
  • ■附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8193IDB

Summary

Global Markets Direct's, 'Peptic Ulcers - Pipeline Review, H1 2016', provides an overview of the Peptic Ulcers pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peptic Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peptic Ulcers and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Peptic Ulcers
  • The report reviews pipeline therapeutics for Peptic Ulcers by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Peptic Ulcers therapeutics and enlists all their major and minor projects
  • The report assesses Peptic Ulcers therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Peptic Ulcers

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Peptic Ulcers
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Peptic Ulcers pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Peptic Ulcers Overview
  • Therapeutics Development
    • Pipeline Products for Peptic Ulcers - Overview
  • Peptic Ulcers - Therapeutics under Development by Companies
  • Peptic Ulcers - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Peptic Ulcers - Products under Development by Companies
  • Peptic Ulcers - Companies Involved in Therapeutics Development
    • Ache Laboratorios Farmaceuticos S/A
    • Astellas Pharma Inc.
    • ChoDang Pharm Co., Ltd.
    • Daewoong Pharmaceutical Co., Ltd.
    • Kukje Pharmaceutical Industry Co., Ltd.
    • RaQualia Pharma Inc.
    • Sequella, Inc.
    • Sihuan Pharmaceutical Holdings Group Ltd.
    • Sinil Pharmaceutical Co., Ltd
    • Yooyoung Pharmaceutical Co., Ltd.
  • Peptic Ulcers - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (ecabet + ranitidine) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (lansoprazole + omeprazole) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • anaprazole sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-6537 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DWJ-206 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KJ-14001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PDI-39 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PMKS-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RQ-00000774 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SI-001002 SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Proton Pump for Peptic Ulcers - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Gastric Ulcers - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SQ-109 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YYD-601 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Peptic Ulcers - Dormant Projects
  • Peptic Ulcers - Discontinued Products
  • Peptic Ulcers - Product Development Milestones
    • Featured News & Press Releases
      • Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies
      • Dec 06, 2010: Sequella Wins FDA Approval To Begin Phase II Trial Of SQ109 In Helicobacter pylori-Associated Duodenal Ulcers
      • Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck
      • Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations
      • Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy
      • Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium)
      • Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium)
      • Jun 01, 2007: AstraZeneca's Prilosec Patents Upheld By Court
      • Dec 12, 2003: Astrazeneca Prilosec Patents Upheld by Federal Appeals Court
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Peptic Ulcers, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Peptic Ulcers - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2016
  • Peptic Ulcers - Pipeline by Astellas Pharma Inc., H1 2016
  • Peptic Ulcers - Pipeline by ChoDang Pharm Co., Ltd., H1 2016
  • Peptic Ulcers - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016
  • Peptic Ulcers - Pipeline by Kukje Pharmaceutical Industry Co., Ltd., H1 2016
  • Peptic Ulcers - Pipeline by RaQualia Pharma Inc., H1 2016
  • Peptic Ulcers - Pipeline by Sequella, Inc., H1 2016
  • Peptic Ulcers - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2016
  • Peptic Ulcers - Pipeline by Sinil Pharmaceutical Co., Ltd, H1 2016
  • Peptic Ulcers - Pipeline by Yooyoung Pharmaceutical Co., Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Peptic Ulcers - Dormant Projects, H1 2016
  • Peptic Ulcers - Dormant Projects (Contd..1), H1 2016
  • Peptic Ulcers - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Peptic Ulcers, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top